Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML

Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function EZH2 mutations are common in myeloid malignancies. We have examined the importance of cellular context for Ezh2 loss during the evolution of acute myeloid leukemia (AML), where we observed stage-specific and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Med
Main Authors: Basheer, Faisal, Giotopoulos, George, Meduri, Eshwar, Yun, Haiyang, Mazan, Milena, Sasca, Daniel, Gallipoli, Paolo, Marando, Ludovica, Gozdecka, Malgorzata, Asby, Ryan, Sheppard, Olivia, Dudek, Monika, Bullinger, Lars, Döhner, Hartmut, Dillon, Richard, Freeman, Sylvie, Ottmann, Oliver, Burnett, Alan, Russell, Nigel, Papaemmanuil, Elli, Hills, Robert, Campbell, Peter, Vassiliou, George S., Huntly, Brian J.P.
Formato: Artigo
Idioma:Inglês
Publicado em: Rockefeller University Press 2019
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6446874/
https://ncbi.nlm.nih.gov/pubmed/30890554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20181276
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados